We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
-$394M
Cap. Flow
-$894M
Cap. Flow %
-41.57%
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$48.4M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$46.1M
3
TSRO
TESARO, Inc.
TSRO
+$22.6M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$21.3M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
XNPT
XENOPORT, INC.
XNPT
+$81.5M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$49.8M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$35.4M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.12%
2 Financials 3.34%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDIT icon
26
Editas Medicine
EDIT
$457M
$23M 1.07%
1,709,400
– –
ONCE
27
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$22.1M 1.03%
368,000
– –
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.36B
$19.4M 0.9%
+4,401,846
New +$17.6M
GKOS icon
29
Glaukos
GKOS
$9.21B
$19M 0.88%
503,277
-480,835
-49% -$15.9M
SEM
30
DELISTED
Select Medical
SEM
$18.3M 0.85%
2,514,253
+70,005
+3% +$445K
IVTY
31
DELISTED
Invuity, Inc
IVTY
$17.6M 0.82%
1,282,598
-44,411
-3% -$528K
AXGN icon
32
Axogen
AXGN
$2.12B
$17.1M 0.8%
1,893,030
-1,488,409
-44% -$12.1M
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$16.3M 0.76%
311,000
-137,000
-31% -$6.54M
BLUE
34
DELISTED
bluebird bio
BLUE
$15.2M 0.71%
17,293
-8,807
-34% -$6.38M
CTMX icon
35
CytomX Therapeutics
CTMX
$788M
$14.8M 0.69%
943,433
– –
TARA icon
36
Protara Therapeutics
TARA
$230M
$14.7M 0.68%
39,262
+461
+1% +$162K
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$12.1M 0.56%
1,307,058
+25,000
+2% +$209K
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
$11.1M 0.52%
1,650,000
-6,711,069
-80% -$26M
AKTX
39
Akari Therapeutics
AKTX
$19.3M
$9.79M 0.46%
1,438
– –
ALIM
40
DELISTED
Alimera Sciences
ALIM
$8.76M 0.41%
391,868
– –
MYOK
41
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.17M 0.38%
499,800
+125,000
+33% +$2.26M
ARDX icon
42
Ardelyx
ARDX
$1.28B
$8.01M 0.37%
618,643
+343,643
+125% +$3.6M
STJ
43
DELISTED
St Jude Medical
STJ
$7.98M 0.37%
+100,000
New +$8.07M
ARLZ
44
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$7.98M 0.37%
1,644,583
– –
SIOX
45
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.95M 0.37%
+71,001
New +$8.52M
EXAS
46
DELISTED
Exact Sciences
EXAS
$6.64M 0.31%
+357,680
New +$6.3M
LOXO
47
DELISTED
Loxo Oncology, Inc
LOXO
$6.57M 0.31%
251,000
– –
BPMC
48
DELISTED
Blueprint Medicines
BPMC
$6.4M 0.3%
+215,586
New +$5.36M
STDY
49
DELISTED
SteadyMed Ltd
STDY
$6.3M 0.29%
1,756,370
+409,626
+30% +$1.4M
OXFD
50
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.83M 0.27%
464,541
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2016 Portfolio in Review

As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XENOPORT, INC., an estimated $81.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $56M.

  • Deerfield Management's largest Q3 2016 buy was NEVRO CORP.: 536,355 shares worth $56M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q3 2016, an estimated $46.1M increase.
  • Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $143M.
  • Deerfield Management fully exited XENOPORT, INC. in Q3 2016, selling an estimated $81.5M.
  • Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
  • Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
  • Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.